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Abstract—Graft-versus-host disease is the onset of an un-
wanted immune response in patients who have undergone bone
marrow transplantation [1]. The effect of this unwanted immune
response is lethal in many cases. The goal of this research is to
reduce the effect of graft-versus-host disease which can possibly
reduce the waiting time for an eligible bone marrow donor
to appear. This paper focused on the MyD88 adaptor protein,
which triggers biochemical signals that can initiate, maintain,
expand, or terminate inflammatory sites [2]. Inflammatory sites
are the areas where the immune cells are gathered to fight foreign
pathogens [1]. Experiments were carried out wherein stem cells
were extracted from C57BL/6 mice and injected into BALB.B
mice. This experiment design establishes the allogeneic bone
marrow transplantation because the minor histocompatibility
complex gene is un-matched between the two strains of mice
while the major histocompatibility complex gene is matched. We
focused on the effect of MyD88 protein deficiency in transplan-
tation recipient. The positive/negative controls for the allogeneic
bone marrow transplantation and MyD88 knockout allogeneic
bone marrow transplantation group were carefully observed for
28 days and assessed for survival, weight, and immune cell
fraction changes. We found that MyD88 protein deficiency yields
prolonged survival in graft-versus-host disease. Data also suggests
that innate immunity is the dominant factor in graft-versus-
host disease, not adaptive immunity. Future experiments with
cytokine analysis in a similar experiment design will provide more
information about the relationship between the innate immunity
and the severity of graft versus host disease.
I. INTRODUCTION
HEMATOPOIETIC stem cell transplantation (HSCT),also commonly known as bone marrow transplantation,
is a treatment option for hematological and immunological
defects, such as autoimmune disease and sickle-cell anaemia
[3]. The general idea of HSCT is to firstly destroy the
hematopoietic stem cells (HSC) as well as other immune
competent cells in the patient to get rid of all defective
cells. Then replace them with a donors robust HSC. The
benefit of performing HSCT is that you do not have to worry
about uncertainty whether treatment was effective or not.
The disadvantage of HSCT is that it is an extremely risky
procedure because of substantial side-effects. With current
technology advances, the surgery must be complimented with
lifetime post-surgery-care to prevent lethal side-effects [3].
In some cases, finding a completely MHC-matched donor is
extremely difficult. In such cases, physicians can choose a
non-ideal solution by performing allogeneic HSCT (usually
matching at MHC locus but mis-matched at MiHC) along with
supplementary immunosuppressive treatments [4]. Ultimately,
in order to achieve the most effective and safest allogeneic
HSCT, the injected donor graft must be free of unwanted
immune cells. The major sources of unwanted immune cell
are mature killer T cells. The recipients immune system will
respond and reject the donors mature killer T cells due to
possibly the mismatched MHC or the minor histocompatibility
antigens (Minor H Ag) of the allogeneic immune competent
cells [3].
The unwanted onset of an immune response after HSCT
is called graft-versus-host-disease (GVHD) [3]. It was widely
recognized that the activation of the adaptive immune system is
the most influential factor of GVHD [1]. One possible way of
GVHD occurring is when the donors mature allogeneic T cells
are co-transported along with the HSC into the recipient [1].
The mature T cells gather at the inflammatory site and attack
the recipients normal cells. Then, after enough time has passed
for the transplanted HSC to go through T cell development,
those newly matured T cells will accelerate the damaging
process. In order to do damage on the recipient cells, an
inflammatory site is required. Without the inflammatory site,
the damage done to the recipient will significantly decrease.
It is worthwhile to investigate the causes of inflammation
because prevention of inflammatory site formation will lead to
no T cells being activated, and thus, no GVHD. Inflammatory
sites can be formed via TLR signalling pathways.
There are two major TLR signalling pathways: the MyD88-
dependent pathway and the MyD88-independent pathway [1].
TLR signalling pathways are needed to convert PAMPs into
communicable nucleus signals [1]. PAMPs are found on
pathogens, since they are usually an indispensable component
of the pathogens structure [2]. Some examples of PAMPs
are lipopolysaccharides, double- and single-stranded RNA,
glycoproteins, flagellin, profillin, and lipopeptides [1] When
any of these PAMPs are recognized and bind to TLRs, a
signal is transduced into the cell to mediate a response. In
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the MyD88-dependent pathway, the TLRs utilize the MyD88
adapter protein to activate the transcription factor NF-?B. NF-
?B then activates transcription, leading to the translatation
of proteins necessary for the immune response. TLRs are
located mainly on the cell membrane and endocytic vesicle
of macrophages and dendritic cells [1].
The hypothesis for this experiment was as follows: “defi-
ciency of MyD88 protein in mice under GVHD condition will
not sufficiently form inflammatory environments, so that the
initiation of GVHD cannot take place in. Therefore, without
the inflammatory environment, activation of donor-originated
T cells would not be fully initiated. As a result, the donor grafts
attack will be delayed because the cells have to find different
ways to trigger inflammation. Therefore, the MyD88 deficient
mouse will survive longer than the allogeneic control group.”
This report has focused on the relationship between GVHD
and MyD88-deficient mice to investigate on the relationship
between the GVHD and the innate immune system.
II. METHOD & PROCEDURE
A. Mice
‘C57BL/6 strain HSC (spleen and bone marrow) into
BALB.B strain model’ was used because it is a well-
established MHC-matched GVHD model (MiHC mis-
matched) [2]. This will represent the allogeneic HSCT because
C57BL/6 and BALB.B genetic strains are matched at MHC-
loci to each other but most other background genes are mis-
matched [2]. Donor and recipient mice were over 6 weeks old
and caged under specific pathogen-free environment. Over the
duration of experiment, no more than 8 mice were kept in one
cage to prevent psychological distress.
B. Induction of GVHD
There were 3 experimental groups:
i) One positive control (allogeneic HSCT) group: C57BL/6
mouse strain into BALB.B mouse strain. The purpose of
this group is to see the effect of allogeneic HSCT.
ii) One negative control (Syngeneic HSCT) group: C57BL/6
mouse strain into C57BL/6 mouse strain. The purpose of
this group is to see the effect of lethal irradiation.
iii) One experimental group: C57BL/6 mouse strain into
MyD88 knockout. BALB.B mouse strain. The purpose
of this group is to see the effect of MyD88 knockout
mouse model in allogeneic HSCT.
Recipient BALB.B mice were irradiated twice with 450 rad
with a 5 hours interval. Then, the C57BL/6 donor mouses
spleen and femur bone marrow cell graft were injected via
I.V. into the recipient BALB.B mouse. The preparation of the
spleen and bone marrow cells are as follows:
1) Spleen Cell Preparation: The extracted spleens were
collected in 1× PBS (8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L
Na2HPO4, 0.24 g/L KH2PO4 at 7.4 pH) solution and stored
at 4 °C up to a maximum of 4 hours. In a PBS wetted 60mm
dish, an autoclaved metal mesh was used to grind the spleen.
Using a pipette, the spleen-PBS solution was transferred to a
15 ml tube using cotton mesh for filtration. Then sample was
centrifuged (at 1500 rpm for 3 minutes) and the supernatant
was removed.
2) Femur & Tibia Bone Marrow Preparation: The extracted
femur and tibia were collected in 1× PBS solution and stored
at 4 °C up to a maximum of 4 hours. In a cold 100 mm dish
on top of ice, a 3 ml syringe was used to extract bone marrow
cells from femur and tibia. Using a pipette, the bone marrow
solution was transferred to a 15 ml tube using cotton mesh
for filtration. The sample was centrifuged (at 1500 rpm for 3
minutes) and the supernatant was removed.
3) Donor Graft Preparation: The total volume of graft
injection was adjusted to 300µl per mouse using 1× PBS.
The graft injection was calculated and adjusted so that each
mice received 2×107 spleen cells and 5×106 femur and tibia
bone marrow cells.
III. RESULTS
The Kaplan-Meier curve of mouse survival in Fig. 1 shows
that the allogeneic control group declined most rapidly among
three experimental designs. At day 21, less than 20% of the
mice survived. The same graph also shows that the survival
rate of the MyD88 deficient group declined almost as slowly
as the syngeneic control group. At day 21, more than 70% of
the mice survived. The Weight Change graph in Fig. 1 shows
that the MyD88 deficient group and allogeneic control group
had similar weight change.
Fig. 1. Kaplan-Meier curve of mouse survival (titled: GVHD Survival) and
weight change of the 3 experimental groups over 28 days. Due to the fast
injection of the donor graft, a mouse in the allogeneic control group died on
the first day.
Generally, graphs show that fractions rapidly increase until
day 4, then, either rapidly decreased or maintained its frac-
tion except for the macrophage and the granulocytes. The
Macrophage Change graph and Granulocyte Change graph
in Fig. 2 show that they continued to increase rapidly and
reached the highest fraction (90%) by day 7. The macrophages,
granulocytes, dendritic cells, B cells, and CD4+ T cells showed
distinct difference in positive and negative control groups.
The Dendritic Cell Change graph in Fig. 3 shows an unusual
fraction change. The dendritic cells in the MyD88 deficient
group mice expectedly showed fraction change patterns as
similar to allogeneic control group until day 14. But after day
14, the dendritic cell fraction notably increased and eventually
reached at similar fraction as the syngeneic control group.
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Fig. 2. Change in the fraction of innate immune cells. Each graph shows
the change that occurred in three different experimental groups over 28 days
using FACS analysis. The result of 8 mice in each experimental group was
collected in to a solution together to acquire the mean value.
Fig. 3. Change in the fraction of adaptive immune cells. Each graph shows
any changes that occurred in three different experimental groups over 28 days
using FACS analysis. The result of 8 mice in each experimental group was
collected in to a solution together to acquire the mean value.
IV. DISCUSSION
The hypothesis was supported, however the data show there
are more factors that need to be considered. For instance,
the MyD88 knockout group lived longer than the allogeneic
control group. This pattern suggests that MyD88 deficient mice
must hold mechanisms that keep them alive longer but still be
severely affected by GVHD.
MyD88 is largely expressed in macrophages and dendritic
cells [1]. It functions to send signals to transcription factors
in the nucleus to stimulate the production and secretion of
inflammatory signals [1]. Although most granulocytes do not
normally express MyD88 proteins, granulocytes do play a
wide range of roles during inflammation. Therefore it is logical
to see the macrophages and the granulocytes in allogeneic
HSCT groups (Fig. 2) maintain very high fraction as shown
in our results ??. We see that the high fraction of both B cells
and T cells demonstrate that the inflammatory site activity
is much higher in the allogeneic HSCT models than in the
syngeneic models due to the GVHD effect.
Macrophages have TLR receptor and MyD88 protein that
can activate MyD88-dependent pathway. The main job of
macrophages is to clean up after metabolic or immune ac-
tivity via phagocytosis. Macrophages phagocytose pathogens
and waste products after apoptosis or necrosis. Granulocytes
(including all: neutrophil, basophil, eosinophils, mast cell, and
natural killer cells) act in many different roles in creating
inflammatory sites [1]. Noting the above two characteristics
of macrophages and granulocytes, we propose that the high
fraction of macrophages and granulocytes show high incidence
of inflammation throughout the body. The fraction of the
innate immune cells which generate inflammatory sites in
allogeneic HSCT group is about 45% higher than in syngeneic
HSCT group, which strongly suggests that innate immunity is
dominant in allogeneic HSCT during GVHD.
The MyD88 deficient group shows a unique pattern in the
dendritic cell fraction that is different than the allogeneic
HSCT control group. The fraction of dendritic cell in the
MyD88-deficient group is much higher in quantity than in
the allogeneic HSCT control group. But, we do not anticipate
that this pattern possesses any importance because the fraction
differences between all three groups are very small anyways.
However some counter-opinion may argue that as dendritic
cells are known to act as messenger cells, it is realistically
possible that the small quantity of dendritic cells can result
in significant consequences to the whole immune system.
That is why the importance of this fraction pattern needs
to be confirmed in future experiments. Once biochemistry of
this pattern is explained in future experiments, more in-depth
understanding of the relationship between the innate immune
system and the adaptive immune system will be gained.
B cells play an important role in adaptive immunity by
producing antibodies [5]. These antibodies are widely used for
immune attack via neutralization of epitopes, direct necrosis or
signalling indicators to other attacking cells [5]. The fraction
of B cells in the syngeneic HSCT group is almost 5 fold
greater than the allogeneic HSCT group. This is the opposite
outcome in comparison to expected outcome and warrants
investigation in future studies.
The results described in this paper present important and
strong evidence to show that innate immune response is
highly active and a dominant factor in GVHD. However, the
design of this experiment could not provide reasoning for the
dendritic cell and B cell fraction patterns observed in GVHD.
Future experiments should investigate the reason for the B cell
fraction being very high in the syngeneic HSCT group but not
in the allogeneic HSCT group. As well, the reason for MyD88
deficient groups dendritic cells fraction pattern to change from
being similar to allogeneic control group into being more-like
syngeneic control group.
V. CONCLUSIONS
Our data provided evidence to suggest that during GVHD,
the number of the innate immune cells dominantly outnumbers
the adaptive immune cells. Therefore, it is more accurate to
say that the innate immune system is more important than the
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adaptive immune system during GVHD. Our results propose
that the innate immune strategies (inflammation without T-
cell involvement) are most influential in GVHD. When the
MyD88 protein is absent in GVHD, the adaptive immune
system tries to compensate for the loss of its messenger
function by producing more dendritic cells. But, we pre-
sumed that increased dendritic cell is a very minor effect
and has a minor contribution to the outcome of GVHD.
On the contrary, the cells that show significant contribution
to the outcome of GVHD are: macrophages, granulocytes
(neutrophils, eosinophils, basophils, mast cell) and B cells.
This report has identified and is suggesting several possible
research directions to study GVHD within MyD88 deficiency.
No specific immune mechanism regarding MyD88 deficiency
was found in this report. The future experiments should
be focused on investigating cytokine secretion in blood or
different organs because the study of cytokines can tell us
the intensity and location of inflammation. The results found
in this experiment have offered a new perspective in thinking
about GVHD; in particular, that it is possible to utilize the
innate immune system to suppress GVHD.
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